B M Paterson

Summary

Publications

  1. ncbi request reprint The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study
    B M Paterson
    Alba Therapeutics Corporation, Baltimore, MD 21201, USA
    Aliment Pharmacol Ther 26:757-66. 2007

Research Grants

Collaborators

Detail Information

Publications1

  1. ncbi request reprint The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study
    B M Paterson
    Alba Therapeutics Corporation, Baltimore, MD 21201, USA
    Aliment Pharmacol Ther 26:757-66. 2007
    ..AT-1001 is an inhibitor of paracellular permeability whose structure is derived from a protein secreted by Vibrio cholerae...

Research Grants1

  1. Oral Formulation of Zonulin Antagonist AT-1001 for Diabe
    BLAKE PATERSON; Fiscal Year: 2006
    ..To develop bioanalytical methods for measuring AT1001 and its physiologic effect AIM 3. To perform Pharmacodynamic and Pharmacokinetic Studies with AT100 AIM 4. Develop optimal oral formulations for AT-1001 ..